- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00844415
Safety and Tolerability of Dabigatran Etexilate in Adolescents
Open-label Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given for 3 Days at the End of Standard Anticoagulant Therapy in Children Aged 12 Years to Less Than 18 Years
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Alberta
-
Edmonton, Alberta, Canada
- 1160.88.00002 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Ottawa, Ontario, Canada
- 1160.88.00001 Boehringer Ingelheim Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
- males or females 12 to less than 18 years of age
- objective diagnosis of primary VTE
- completion of planned treatment course with LMWH or OAC for primary VTE
- written informed consent by parent (legal guardian) and patient assent
Exclusion criteria:
- weight less than 32 kg
- conditions associated with increased risk of bleeding
- severe renal dysfunction or requirement for dialysis
- active infective endocarditis
- hepatic disease
- pregnant females or females not using medically accepted contraceptive method
- anemia or thrombocytopenia
- use of prohibited or restricted drug within previous week
- received investigational drug within past 30 days
- unreliable patients or patients who have any condition that would not allow safe participation in study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: dabigatran etexilate
open label; patient to receive dabigatran etexilate BID for three days
|
2.14 mg/kg BID to a max 150 mg BID
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Patients With Bleeding Events (Major and Minor)
Tijdsspanne: From Screening until 30 days after first drug administration (end of trial visit)
|
Patients were carefully assessed for signs and symptoms of bleeding. Bleeding was to be classified as major or minor. Major bleeding had to satisfy one or more of the following criteria: Overt bleeding associated with a decrease in haemoglobin of at least 2 g/dL in 24 hours, Overt bleeding requiring a transfusion of red blood cells, Overt bleeding which was retroperitoneal, intracranial, intraocular, or intraarticular, any overt bleeding deemed by the attending physician to require discontinuation of study medication. Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. |
From Screening until 30 days after first drug administration (end of trial visit)
|
Number of Patients With Adverse Events
Tijdsspanne: From Screening until 30 days after first drug administration (end of trial visit)
|
Patients with treatment drug related adverse events (DRAEs) and serious adverse events (SAEs) are reported separately for on-treatment and post-treatment period.
Events were considered "on-treatment" if occurring within 72 hours after last drug administration.
|
From Screening until 30 days after first drug administration (end of trial visit)
|
Plasma Concentration of Free Dabigatran
Tijdsspanne: 3 days
|
Plasma concentration of free dabigatran measured at 72 hours after first dose
|
3 days
|
Plasma Concentration of Total Dabigatran
Tijdsspanne: Day 3
|
Plasma concentration of total dabigatran measured at 72 hours after first dose
|
Day 3
|
Thrombin Time (TT) Centrally Measured
Tijdsspanne: Day 3
|
Measurement of TT was performed locally and centrally by Hemoclot Thrombin Inhibitor clotting assay.
|
Day 3
|
TT Locally Measured
Tijdsspanne: Day 3
|
Measurement of TT was performed locally and centrally by Hemoclot Thrombin Inhibitor clotting assay.
|
Day 3
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Activated Partial Thromboplastin Time (aPTT) Centrally Measured
Tijdsspanne: Day 3
|
Measurement of aPTT was performed locally and centrally using validated assays.
|
Day 3
|
aPTT Locally Measured
Tijdsspanne: Day 3
|
Measurement of aPTT was performed locally and centrally using validated assays.
|
Day 3
|
Ecarin Clotting Time (ECT)
Tijdsspanne: Day 3
|
Measurement of ECT was performed locally and centrally using validated assays.
Descriptive statistics is only performed for the centrally measured ECT.
|
Day 3
|
Patients With Clinically Relevant Changes in Any Laboratory Parameter, Electrocardiogram (ECG) or Vital Signs
Tijdsspanne: Baseline and 3 days
|
Changes in any laboratory parameter, ECG or vital signs were judged clinically relevant by the investigator.
|
Baseline and 3 days
|
Occurences of Clinical Outcome
Tijdsspanne: 3 days
|
Occurrences of clinical outcomes including recurrent venous thrombolic event (VTE), post thrombotic syndrome (PTS), pulmonary emboli (PEs), and total and VTE related mortality objectively assessed for example by ultrasound, venography or computed chromatography (CT) scan (based on the thrombus location).
Number of patients with particular clinical outcome are reported.
|
3 days
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1160.88
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op dabigatran etexilate
-
Centre Hospitalier Universitaire de Saint EtienneGroupe de Recherche sur la ThromboseVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooidBloeding | BoezemfibrillerenVerenigde Staten
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimUppsala University; Population Health Research InstituteVoltooidHartinfarct | BoezemfibrillerenVerenigde Staten, Argentinië, Australië, Oostenrijk, België, Brazilië, Bulgarije, Canada, China, Colombia, Tsjechië, Denemarken, Finland, Frankrijk, Duitsland, Griekenland, Hongkong, Hongarije, Indië, Israël, Italië, Japan, Korea, republiek... en meer
-
Boehringer IngelheimVoltooid